Compositions and methods for treating cns disorders
AssigneeSage Therapeutics, Inc.
InventorsAlbert J. Robichaud, Gabriel Martinez Botella, Francesco G. Salituro, Boyd L. Harrison
Life of this patent
Estimating the term…
Abstract
Described herein are neuroactive steroids of the Formula (I): or a pharmaceutically acceptable salt thereof; wherein , A, R1, R2, and R3 are as defined herein. Such compounds are envisioned, in certain embodiments, to behave as GABA modulators. The present invention also provides pharmaceutical compositions comprising a compound of the present invention and methods of use, e.g., for treating a subject suffering from a disease or disorder described herein.
Claims34
A compound of the Formula (I):
- or a pharmaceutically acceptable salt thereof;
- wherein:
- Ring A is aryl or heteroaryl;
- R1 is hydrogen, C1-3 alkyl, C2-6 alkenyl, or C3-6 carbocylyl;
- R2 is absent or hydrogen;
- R3 is hydrogen, alkyl, or —CH2OR3A, wherein RA3 is hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, heteroaryl, or C3-6 carbocyclyl;
- represents a single or double bond, wherein when one is a double bond, the other is a single bond;
- wherein when R1 is —CH3, R2 is hydrogen in the alpha configuration, and R3 is —CH3, then A is aryl.
3-20. (canceled)
24-41. (canceled)
45-62. (canceled)
A method of inducing sedation and/or anesthesia in a subject, comprising administering to the subject an effective amount of a compound of the Formula (I):
- or a pharmaceutically acceptable salt thereof;
- wherein:
- Ring A is aryl or heteroaryl;
- R1 is hydrogen, C1-3 alkyl, C2-6 alkenyl, or C3-6 carbocylyl;
- R2 is absent or hydrogen;
- R3 is hydrogen, alkyl, or —CH2OR3A, wherein R3A is hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, aryl heteroaryl, or C3-6 carbocyclyl;
- represents a single or double bond, wherein when one is a double bond, the other is a single bond;
- wherein when R1 is —CH3, R2 is hydrogen in the alpha configuration, and R3 is —CH3, then A is aryl.
A method for treating seizure in a subject, comprising administering to the subject an effective amount of a compound of the Formula (I):
- or a pharmaceutically acceptable salt thereof;
- wherein:
- Ring A is aryl or heteroaryl;
- R1 is hydrogen, C1-3 alkyl, C2-6 alkenyl, or C3-6 carbocylyl;
- R2 is absent or hydrogen;
- R3 is hydrogen, alkyl, or —CH2OR3A, wherein R3A is hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, heteroaryl, or C3-6 carbocyclyl;
- represents a single or double bond, wherein when one is a double bond, the other is a single bond;
- wherein when R1 is —CH3, R2 is hydrogen in the alpha configuration, and R3 is —CH3, then A is aryl.
A method for treating epilepsy in a subject, the method comprising administering to the subject an effective amount of a compound of the Formula (I):
- or a pharmaceutically acceptable salt thereof;
- wherein:
- Ring A is aryl or heteroaryl;
- R1 is hydrogen, C1-3 alkyl, C2-6 alkenyl, or C3-6 carbocylyl;
- R2 is absent or hydrogen;
- R3 is hydrogen, alkyl, or —CH2OR3A, wherein R3A is hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, heteroaryl, or C3-6 carbocyclyl;
- represents a single or double bond, wherein when one is a double bond, the other is a single bond;
- wherein when R1 is —CH3, R2 is hydrogen in the alpha configuration, and R3 is —CH3, then A is aryl.
A method for treating status epilepticus (SE) in a subject, the method comprising administering to the subject an effective amount of a compound of the Formula (I):
- or a pharmaceutically acceptable salt thereof;
- wherein:
- Ring A is aryl or heteroaryl;
- R1 is hydrogen, C1-3 alkyl, C2-6 alkenyl, or C3-6 carbocylyl;
- R2 is absent or hydrogen;
- R3 is hydrogen, alkyl, or —CH2OR3A, wherein R3A is hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, heteroaryl, or C3-6 carbocyclyl;
- represents a single or double bond, wherein when one is a double bond, the other is a single bond;
- wherein when R1 is —CH3, R2 is hydrogen in the alpha configuration, and R3 is —CH3, then A is aryl.
(canceled)
A method for treating a CNS-related disorder in a subject in need thereof, comprising administering to the subject an effective amount of a compound of Formula (I):
- or a pharmaceutically acceptable salt thereof;
- wherein:
- Ring A is aryl or heteroaryl;
- R1 is hydrogen, C1-3 alkyl, C2-6 alkenyl, or C3-6 carbocylyl;
- R2 is absent or hydrogen;
- R3 is hydrogen, alkyl, or —CH2OR3A, wherein R3A is hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, heteroaryl, or C3-6 carbocyclyl;
- represents a single or double bond, wherein when one is a double bond, the other is a single bond;
- wherein when R1 is —CH3, R2 is hydrogen in the alpha configuration, and R3 is —CH3, then A is aryl.
84-100. (canceled)
A kit comprising a solid composition comprising a compound of Formula (I):
- or a pharmaceutically acceptable salt thereof;
- wherein:
- Ring A is aryl or heteroaryl;
- R1 is hydrogen, C1-3 alkyl, C2-6 alkenyl, or C3-6 carbocylyl;
- R2 is absent or hydrogen;
- R3 is hydrogen, alkyl, or —CH2OR3A, wherein R3A is hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, heteroaryl, or C3-6 carbocyclyl;
- represents a single or double bond, wherein when one is a double bond, the other is a single bond;
- wherein when R1 is —CH3, R2 is hydrogen in the alpha configuration, and R3 is —CH3, then A is aryl.
Dependencies are inferred from the claim text.